ADCT ADC Therapeutics Corp: Net earnings per one share for the last twelve months

Public company logo of ADC Therapeutics S.A. (ADCT)

ADC Therapeutics (ADCT) develops advanced molecules for the targeted destruction of blood tumors, offering patients a gentler alternative to traditional treatment. However, high promotion and R&D expenses leave the company deeply unprofitable, hindering the creation of a sustainable cash flow. This chart on GURU.Markets shows EPS at 63.10, while patent protection and strict FDA requirements create a powerful barrier to entry for new players.

ADC Therapeutics S.A. (ADCT): Net earnings per share (EPS TTM) from 02/11/2024 to 11/17/2026

ADC Therapeutics SA - analytical breakdowns and key metrics (ADCT)

- share price and expert price forecast:
- company stock capitalization data:
Fundamental company valuation:ADC Therapeutics
Mass-produced product of adctherapeutics.com

ADC Therapeutics relies on the commercialization of an innovative conjugate for lymphoma therapy. By analyzing the annual percentage growth of EPS TTM, an investor tracks the rate of change in net income per share over a rolling year. This metric measures the efficiency of converting revenue into shareholder value, neutralizing short-term quarterly fluctuations. A stable trajectory for this indicator confirms the resilience of the operating model within the biotechnological cycle.